COVID-19 Pandemic-Related Changes in Rates of Neonatal Abstinence Syndrome

Sarka Lisonkova; Jeffrey N Bone; Qi Wen; Giulia M Muraca; Joseph Y Ting; Neda Razaz; K S Joseph

doi:10.1001/jamanetworkopen.2024.1651

COVID-19 Pandemic-Related Changes in Rates of Neonatal Abstinence Syndrome

JAMA Netw Open. 2024 Mar 4;7(3):e241651. doi: 10.1001/jamanetworkopen.2024.1651.

Authors

Sarka Lisonkova^{1

2}, Jeffrey N Bone^{1

3}, Qi Wen¹, Giulia M Muraca^{4

5}, Joseph Y Ting⁶, Neda Razaz⁷, K S Joseph^{1

2}

Affiliations

¹ Department of Obstetrics and Gynaecology, University of British Columbia and the Children's and Women's Hospital and Health Centre of British Columbia, Vancouver, British Columbia, Canada.
² School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
³ Division of Biostatistics, British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
⁴ Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
⁵ Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada.
⁶ Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
⁷ Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

No abstract available

Plain language summary

This cross-sectional study examines COVID-19 pandemic–related changes in rates of neonatal abstinence syndrome (NAS) and whether infants in urban or rural areas and those with low socioeconomic status were disproportionately affected.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Analgesics, Opioid / therapeutic use
COVID-19*
Humans
Infant, Newborn
Neonatal Abstinence Syndrome* / drug therapy
Neonatal Abstinence Syndrome* / epidemiology
Opioid-Related Disorders* / epidemiology
Pandemics

Substances

Analgesics, Opioid

Grants and funding

CIHR/Canada